Asensus Surgical Acquisition Marks End of Public Trading Era

The publicly traded chapter of Asensus Surgical has concluded following its complete acquisition by the KARL STORZ Group. The company’s shares have been delisted from the NYSE American Exchange, eliminating any further trading activity for former shareholders.

KARL STORZ Endoscopy-America has successfully purchased all outstanding shares of Asensus Surgical at a price of $0.35 per share. Shareholder approval facilitated the transaction’s completion, transforming Asensus Surgical into a wholly-owned subsidiary. This strategic move eliminates the surgical robotics specialist’s independent market presence.

The acquisition centers around KARL STORZ’s objective to leverage Asensus Surgical’s expertise with the Senhance robotic platform and the ongoing development of its second-generation LUNA Read more...